HORSHAM, Pa. (September 11, 2024) – Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved...

MONDAY, Sept. 16, 2024 -- The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for the treatment of adults with moderately to...

MONDAY, Sept. 16, 2024 -- The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for the treatment of adults with moderately to...

With this latest approval, JNJ's Tremfya is approved for a total of three immunology indications.

With this latest approval, JNJ's Tremfya is approved for a total of three immunology indications.

INDIANAPOLIS, Sept. 13, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) approved...

Novartis announced that the US Food and Drug Administration (FDA) has approved Kisqali (ribociclib) in combination with an aromatase inhibitor (AI)...

FDA approves J&J's Tremfya for ulcerative colitis. NVO's oral obesity pill, amycretin, shows faster weight loss than weekly injection, Wegovy.

WEDNESDAY, Sept. 18, 2024 -- The U.S. Food and Drug Administration has approved Ebglyss (lebrikizumab-lbkz) for adults and children aged 12 years and...

WEDNESDAY, Sept. 18, 2024 -- Women with early stage breast cancer may now take Kisquali, a medication already approved for advanced disease, following...